Janssen Sciences Ireland Uc

Janssen Sciences Ireland Unlimited Company

Aligos Therapeutics, Inc.

Amgen Inc.

Janssen R&d Ireland

Medivir Ab

Tibotec Pharmaceuticals Ltd.

Janssen Research & Development Ireland

David Craig McGowan

Pierre Jean-Marie Bernard Raboisson

Tim Hugo Maria Jonckers

Stefaan Julien Last

Werner Embrechts

Serge Maria Aloysius Pieters

Koen Vandyck

Jerome Deval

Matthew W Martin

Jérôme Émile Georges Guillemont

Werner Constant Johan Embrechts

Wendy Mia Albert Balemans

Leonid Beigelman

Joseph J Nunes

Stuart C Chaffee

John Laird Buchanan

Abdellah Tahri

Jean-François Bonfanti

Brian Lewis Hodous

Sandrine Marie Helene Vendeville

Lili Hu

Herman Augustinus De Kock

Ludwig Paul Cooymans

Jérôme Michel Claude Fortin

Christophe Francis Robert Nestor Buyck

Frédéric Marc Maurice Doublet

Erin F DiMauro

Wim Van De Vreken

Samuel Dominique Demin

Jaromir Vlach

William H Buckner

Ning Xi

Craig E Masse

Andrew Stewart Tasker

Joseph L Kim

Jean-Christophe P Harmange

Vinod Francis Patel

Jean E Bemis

Matthew M Weiss

Frank Kayser

Shon Booker

Yuan Cheng

Shimin Xu

David Francis Alain Lançois

Magali Madeleine Simone Motte

Steven F Bellon

Daniel La

Lucian V DiPietro

Russell Graceffa

Tae-Seong Kim

Philippe Muller

Julie Germain

Deborah Choquette

Michele Potashman

Gregory J Habgood

Sandrine Vendeville

Jinqian Liu

Guillaume Jean Maurice Mercey

Yannick Debing

George Borg

Douglas A Whittington

Ning Chen

Brian K Albrecht

Daniel Elbaum

Anthony B Reed

Ryan D White

Victor J Cee

Xiaotian Zhu

Dominique Louis Nestor Ghislain Surleraux

Wim Gaston Verschueren

Anil Koul

Rajiv Sharma

Jerôme Emile Georges Guillemont

Tongfei Wu

Kenneth Simmen

Bengt Bertil Samuelsson

Antitsa Dimitrova Stoycheva

Christopher Neil Farthing

Perry M Novak

Åsa Annica Kristina Rosenquist

Karl Magnus Nilsson

Shannon Rumfelt

Karina Romero

Sarah Lively

Essa H Hu

Geerwin Yvonne Paul Haché

Philip R Olivieri

Roxanne Kay Kunz

Jiasheng Fu

XianYun Jiao

Geert Rombouts

Antoine Benjamin Michaut

Dmitry Antonov

Pierre Jean-Marie Raboisson

Anna Karin Gertrud Linnea Belfrage

Stephen J Shuttleworth

Francois Gonzalvez

Alexander David Frenkel

Teresa L Marshall

Disclosed herein are compounds of Formula I:TL-L-CE-HD  (I)or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.

Modulators of THR-β and methods of use thereof

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

Methods and compositions for targeting PD-L1

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Bicyclic compounds

Disclosed herein are compounds of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.

Bicyclic pyridazinones and methods of use thereof

Disclosed herein are compounds of Formula I': or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above compounds.

Modulators of THR-&#x3b2; and methods of use thereof

Disclosed herein are compounds of Formula I': or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.

Oxindoles and methods of use thereof

Disclosed herein are compounds of Formula I&#x2033;: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.

2-pyridones and methods of use thereof

This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.

Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases

Compounds targeting PRMT5

The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Aryl substituted pyrimidines for use in influenza virus infection

The present invention relates to purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Purine derivatives for the treatment of viral infections

Disclosed herein are compounds of Formula I:TL-L-CE-HD&#x2003;&#x2003;(I)or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds. 

This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Dihydropyranopyrimidines for the treatment of viral infections

This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.

Pyrimidine prodrugs for the treatment of viral infections and further diseases

Growing community of inventors

Brussels, Belgium

David Craig McGowan